Overview

Phase 1 Study of PYX-201 in Solid Tumors

Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the recommended dose(s) of PYX-201 for participants with relapsed/refractory (R/R) solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Pyxis Oncology, Inc